Correlation Between Biotechnology Portfolio and American Funds

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Biotechnology Portfolio and American Funds at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biotechnology Portfolio and American Funds into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biotechnology Portfolio Biotechnology and American Funds Fundamental, you can compare the effects of market volatilities on Biotechnology Portfolio and American Funds and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biotechnology Portfolio with a short position of American Funds. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biotechnology Portfolio and American Funds.

Diversification Opportunities for Biotechnology Portfolio and American Funds

0.64
  Correlation Coefficient

Poor diversification

The 3 months correlation between Biotechnology and American is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Biotechnology Portfolio Biotec and American Funds Fundamental in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on American Funds Funda and Biotechnology Portfolio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biotechnology Portfolio Biotechnology are associated (or correlated) with American Funds. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of American Funds Funda has no effect on the direction of Biotechnology Portfolio i.e., Biotechnology Portfolio and American Funds go up and down completely randomly.

Pair Corralation between Biotechnology Portfolio and American Funds

Assuming the 90 days horizon Biotechnology Portfolio Biotechnology is expected to under-perform the American Funds. But the mutual fund apears to be less risky and, when comparing its historical volatility, Biotechnology Portfolio Biotechnology is 1.02 times less risky than American Funds. The mutual fund trades about -0.15 of its potential returns per unit of risk. The American Funds Fundamental is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  8,539  in American Funds Fundamental on October 23, 2024 and sell it today you would lose (258.00) from holding American Funds Fundamental or give up 3.02% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Biotechnology Portfolio Biotec  vs.  American Funds Fundamental

 Performance 
       Timeline  
Biotechnology Portfolio 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biotechnology Portfolio Biotechnology has generated negative risk-adjusted returns adding no value to fund investors. In spite of weak performance in the last few months, the Fund's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the fund investors.
American Funds Funda 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days American Funds Fundamental has generated negative risk-adjusted returns adding no value to fund investors. In spite of fairly strong fundamental indicators, American Funds is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Biotechnology Portfolio and American Funds Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Biotechnology Portfolio and American Funds

The main advantage of trading using opposite Biotechnology Portfolio and American Funds positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biotechnology Portfolio position performs unexpectedly, American Funds can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in American Funds will offset losses from the drop in American Funds' long position.
The idea behind Biotechnology Portfolio Biotechnology and American Funds Fundamental pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Bonds Directory
Find actively traded corporate debentures issued by US companies